164 related articles for article (PubMed ID: 32647190)
1. Monitoring indices of bone inflammatory activity of the jaw using SPECT bone scintigraphy: a study of ARONJ patients.
Hata H; Kitao T; Sato J; Asaka T; Ohga N; Imamachi K; Hirata K; Shiga T; Yamazaki Y; Kitagawa Y
Sci Rep; 2020 Jul; 10(1):11385. PubMed ID: 32647190
[TBL] [Abstract][Full Text] [Related]
2. Quantitative evaluation of anti-resorptive agent-related osteonecrosis of the jaw using bone single photon emission computed tomography in clinical settings: relationship between clinical stage and imaging.
Okui T; Kobayashi Y; Tsujimoto M; Satoh K; Toyama H; Matsuo K
Ann Nucl Med; 2020 Sep; 34(9):620-628. PubMed ID: 32557015
[TBL] [Abstract][Full Text] [Related]
3. Quantitative bone scan imaging using BSI and BUV: an approach to evaluate ARONJ early.
Yamamoto Y; Mitsunaga S; Horikawa A; Hino A; Kurihara H
Ann Nucl Med; 2020 Jan; 34(1):74-79. PubMed ID: 31705367
[TBL] [Abstract][Full Text] [Related]
4. Effect of morphological findings in computed tomography on the quantitative values in single-photon emission computed tomography for patients with antiresorptive agent-related osteonecrosis of the jaw: a cross-sectional study.
Kobayashi Y; Okui T; Tsujimoto M; Ikeda H; Satoh K; Kanamori D; Fujii N; Toyama H; Matsuo K
Ann Nucl Med; 2021 Jul; 35(7):853-860. PubMed ID: 33997910
[TBL] [Abstract][Full Text] [Related]
5. Histopathological findings affect quantitative values of single photon emission computed tomography in patients with antiresorptive agent-related osteonecrosis of the jaws.
Okui T; Kobayashi Y; Isomura M; Tsujimoto M; Satoh K; Toyama H
Fujita Med J; 2023 Aug; 9(3):186-193. PubMed ID: 37554942
[TBL] [Abstract][Full Text] [Related]
6. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
7. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
[TBL] [Abstract][Full Text] [Related]
8. Nonexposed antiresorptive agent-related osteomyelitis of the jaw: a single-center cohort study.
Watanabe T; Yoshida T; Akizuki S; Yamanaka S; Nakao K; Fukuhara S; Asai K; Uozumi R; Bessho K
J Bone Miner Metab; 2022 Jul; 40(4):657-662. PubMed ID: 35534635
[TBL] [Abstract][Full Text] [Related]
9. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
Shibahara T
Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
[TBL] [Abstract][Full Text] [Related]
10. Bone scan index of the jaw: a new approach for evaluating early-stage anti-resorptive agents-related osteonecrosis.
Watanabe S; Nakajima K; Mizokami A; Yaegashi H; Noguchi N; Kawashiri S; Inokuchi M; Kinuya S
Ann Nucl Med; 2017 Apr; 31(3):201-210. PubMed ID: 27995542
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease.
Fujieda Y; Doi M; Asaka T; Ota M; Hisada R; Ohnishi N; Kono M; Kameda H; Nakazawa D; Kato M; Amengual O; Takahata M; Yasuda S; Kitagawa Y; Atsumi T
J Bone Miner Metab; 2020 Jul; 38(4):581-588. PubMed ID: 32076874
[TBL] [Abstract][Full Text] [Related]
12. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in urological malignancies: a multi-center retrospective study.
Sakai Y; Shindo T; Sato S; Takahashi A; Kunishima Y; Kato R; Itoh N; Okada M; Tachiki H; Taguchi K; Takayanagi A; Hotta H; Horita H; Matsukawa M; Matsuki M; Nishiyama K; Miyazaki A; Hashimoto K; Tanaka T; Masumori N
J Bone Miner Metab; 2021 Jul; 39(4):661-667. PubMed ID: 33704573
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of quantitative bone SPECT/CT for medication-related osteonecrosis of the jaw in clinical settings.
Moridera K; Kitajima K; Yoshikawa K; Takaoka K; Tsuchitani T; Noguchi K; Kishimoto H; Yamakado K
Jpn J Radiol; 2022 May; 40(5):492-499. PubMed ID: 34851501
[TBL] [Abstract][Full Text] [Related]
14. Synchronous antiresorptive osteonecrosis of the jaws and breast cancer metastasis.
Flores IL; dos Santos-Silva AR; Della Coletta R; Vargas PA; Lopes MA
Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Mar; 117(3):e264-8. PubMed ID: 24528798
[TBL] [Abstract][Full Text] [Related]
15. Quantitative SPECT/CT imaging for medication-related osteonecrosis of the jaw: a preliminary study using volume-based parameters, comparison with chronic osteomyelitis.
Ogura I; Kobayashi E; Nakahara K; Igarashi K; Haga-Tsujimura M; Toshima H
Ann Nucl Med; 2019 Oct; 33(10):776-782. PubMed ID: 31342316
[TBL] [Abstract][Full Text] [Related]
16. Continuous Mandibular Nerve Block for Intractable Mandibular Pain Due to Antiresorptive Agent-Related Osteonecrosis of the Jaw: A Case Report.
Fujimoto D; Obata N; Motoyama Y; Sato H; Takao Y; Mizobuchi S
Kobe J Med Sci; 2020 Nov; 66(3):E90-E93. PubMed ID: 33431781
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage.
Watanabe T; Asai K; Fukuhara S; Uozumi R; Bessho K
PLoS One; 2021; 16(1):e0244859. PubMed ID: 33395446
[TBL] [Abstract][Full Text] [Related]
18. Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study.
Nashi M; Hirai T; Iwamoto T; Takenobu T
J Bone Miner Metab; 2022 Nov; 40(6):1014-1020. PubMed ID: 36166107
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of quantitative bone SPECT/CT for evaluating medication-related osteonecrosis of the jaw treatment response.
Moridera K; Kitajima K; Yoshikawa K; Takaoka K; Tsuchitani T; Noguchi K; Kishimoto H; Yamakado K
Jpn J Radiol; 2023 Jul; 41(7):760-767. PubMed ID: 36656541
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGFR therapy is one of the healing inhibitors of antiresorptive-related osteonecrosis of the jaw.
Kanno C; Kaneko T; Endo M; Kitabatake T; Sakuma T; Kanaya Y; Watanabe Y; Hasegawa H
J Bone Miner Metab; 2021 May; 39(3):423-429. PubMed ID: 33196901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
